ZURICH– (BUSINESS WIRE) – Xlife Sciences AG: M.M. Warburg stelt koersdoel vast op 55,75 euro

De analisten van Deutsche Bankhaus M.M. Warburg hebben in hun onlangs gepubliceerde rapport het koersdoel voor de aandelen van de Zwitserse beheermaatschappij Xlife Sciences AG (Xetra: XLS) vastgesteld op 55,75 EUR. De winst van het bedrijf voor het boekjaar 2020 wordt verwacht op 10,4 miljoen euro en de EBITDA op 10,5 miljoen euro. Vanwege het hoogwaardige portfolio van life science-projecten, heeft M.M. Warburg ziet een aanhoudend sterke winstgroei.

Volgens het rapport zijn de belangrijkste redenen voor de positieve waardering: de hoge kwaliteit van de 21 projecten van Xlife, de gestroomlijnde kostenstructuur van het bedrijf en de ongelooflijke pijplijn van mogelijke toekomstige exits. Volgens analisten van Warburg wordt het aandeel verhandeld met een aanzienlijke korting tegen de huidige prijs van ongeveer 38 euro vanwege de recupereerbaarheid van de projectbedrijven. Oliver R. Baumann, CEO van Xlife, is blij met het rapport. “Dit bevestigt dat onze focus op diversificatie in de vier gebieden van technologieplatforms, biotechnologie, medische technologie en kunstmatige intelligentie een groot potentieel biedt”. Volgens Baumann is een investering in de vroege fase van een life science-project ook zeer interessant vanuit een risicoperspectief, aangezien de hefboomwerking groter is vanwege de lagere kapitaalinvestering en de kans op succes van een project in de “proof of concept-fase” zijn over het algemeen hoger.

Xlife Sciences AG: M.M. Warburg sets price target to EUR 55.75

ZURICH–(BUSINESS WIRE)– Xlife Sciences AG: M.M. Warburg sets price target to EUR 55.75

In their recently published report, the analysts of Deutsche Bankhaus M.M. Warburg set the price target for the shares of the Swiss management company, Xlife Sciences AG (Xetra: XLS) to EUR 55.75. The company’s earnings for the financial year 2020 are expected at 10.4 million euros and EBITDA is expected at 10.5 million euros. Due to the high quality portfolio of life science projects, M.M. Warburg sees continued strong earnings growth.

According to the report, the main reasons for the positive valuation are: the high quality of Xlife’s 21 projects, the company’s lean cost structure and the incredible pipeline of possible future exits. According to Warburg analysts, the share is trading at a significant discount at the current price of around 38 euros due to the recoverability of the project companies. Xlife CEO Oliver R. Baumann is happy about the report. “This confirms that our focus on diversification in the four areas of technology platforms, biotechnology, medical technology and artificial intelligence offers great potential”. According to Baumann, an investment at the early stage of a life science project is also highly interesting from a risk perspective as the leverage is greater due to the lower capital investment and the chances for success of a project in the “proof of concept phase” are generally higher.

Strong EBITDA growth until 2022

The management has set ambitious goals for the future. The EBITDA is expected to rise to 67 million euros and the net profit to almost 60 million euros as early as 2022, with an EBITDA margin of 92%. At a strategic level, Xlife intends to make greater use of the synergies between the projects and aims to further increase profitability, with a focus on licensing agreements. In the long term, the company aims to establish itself as a centre of excellence for antibodies, human genetics and personalised medicine and will further diversity its early-stage project portfolio. The long-term dividend yield target is at 3-4%.

About Xlife Sciences AG

Xlife Sciences AG (m:access: XLS) is a Swiss company with focus on investing in promising technologies in the life science industry. Xlife Sciences AG is building the bridge from research and development to healthcare markets. Together with industrial partners or universities, Xlife Sciences AG leads projects through the proof-of-concept phase after an invention disclosure or start-up. Subsequently, the firm focuses on out-licensing or selling the company, often with a combination of a strategic partnership. Xlife Sciences AG offers its investors direct access to the further development of innovative and future-oriented technologies at a very early stage.

For more information, please visit: www.xlifesciences.ch

Additional features: M.M. Warburg, Research Publication on Xlife Sciences AG

View source version on businesswire.com: https://www.businesswire.com/news/home/20201102005456/en/

Contacts

Oliver R. Baumann

+41-44-385-84-68

oliver.baumann@xlifesciences.ch